tipepidine has been researched along with ADDH in 3 studies
tipepidine: RN given refers to parent cpd
| Excerpt | Relevance | Reference |
|---|---|---|
| " Phase II study was conducted to examine the effects of TS-141 30 (once a day), 60 (once a day), 120 mg (60 mg twice a day), or placebo, that is within the exposure in the maximum dosage of Asverin, in children and adolescents with ADHD, and was designed as an 8-week treatment, randomized, parallel group, double-blind, placebo-controlled trial recruiting 6-17-year-old children and adolescents diagnosed with ADHD." | 2.94 | Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder. ( Iwamori, S; Mizuno-Yasuhira, A; Nishino, I; Okada, T; Saito, K; Saito, T; Shinoda, S; Tomoda, A; Umeuchi, H; Urano, H; Yamashita, Y, 2020) |
| " The frequencies of adverse events were similar between the two groups." | 2.90 | Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Bagheri, S; Dehbozorghi, S; Mohammadi, MR; Moradi, K; Shokraee, K, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, T | 1 |
| Yamashita, Y | 1 |
| Tomoda, A | 2 |
| Okada, T | 1 |
| Umeuchi, H | 1 |
| Iwamori, S | 1 |
| Shinoda, S | 1 |
| Mizuno-Yasuhira, A | 1 |
| Urano, H | 1 |
| Nishino, I | 1 |
| Saito, K | 1 |
| Dehbozorghi, S | 1 |
| Bagheri, S | 1 |
| Moradi, K | 1 |
| Shokraee, K | 1 |
| Mohammadi, MR | 1 |
| Akhondzadeh, S | 1 |
| Takiguchi, S | 1 |
| Fujisawa, TX | 1 |
| Yatsuga, C | 1 |
| Kumazaki, H | 1 |
| Fujioka, T | 1 |
| Suzuki, H | 1 |
| Matsuzaki, H | 1 |
| Kosaka, H | 1 |
| Tanaka, S | 1 |
2 trials available for tipepidine and ADDH
| Article | Year |
|---|---|
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2020 |
Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2019 |
1 other study available for tipepidine and ADDH
| Article | Year |
|---|---|
Effectiveness of oral tipepidine administration for children with attention deficit/hyperactivity disorder: A 4-week, open-label clinical study.
Topics: Administration, Oral; Attention Deficit Disorder with Hyperactivity; Child; Follow-Up Studies; Human | 2015 |